Dr. Martens plc (LON:DOCS - Get Free Report) shares fell 0.1% on Wednesday . The company traded as low as GBX 63.15 ($0.82) and last traded at GBX 63.15 ($0.82). 561,160 shares changed hands during trading, a decline of 63% from the average session volume of 1,520,157 shares. The stock had previously closed at GBX 63.20 ($0.82).
Dr. Martens Stock Down 4.8 %
The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The stock has a market capitalization of £564.01 million, a PE ratio of 8.24, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. The business's fifty day moving average price is GBX 69.58 and its two-hundred day moving average price is GBX 65.21.
Dr. Martens Cuts Dividend
The firm also recently declared a dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Thursday, March 6th will be issued a GBX 0.85 ($0.01) dividend. This represents a yield of 1.47%. The ex-dividend date is Thursday, March 6th. Dr. Martens's payout ratio is 42.53%.
About Dr. Martens
(
Get Free Report)
Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.
The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.
Further Reading
Before you consider Dr. Martens, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dr. Martens wasn't on the list.
While Dr. Martens currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.